flow cytometry sony id7000 spectral cell analyzer  (Sony)

Journal: Nature Communications

Article Title: Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity

doi: 10.1038/s41467-025-59622-4

Figure Lengend Snippet: a Tumor growth in IgMi mice. IgMi or C57BL/6 mice were s.c. implanted with 1 × 10 6 MC38 tumor cells per mouse. Tumor growth curves were pooled from 2 independent experiments. b , c Shown are frequencies of GC B cells ( b ) in IgMi ( N = 9) vs C57BL/6 ( N = 8) mice and frequencies of plasmablast ( c ) in IgMi ( N = 8) vs C57BL/6 ( N = 8) mice in draining LNs on day 7 post-inoculation of MC38 tumor cells. d Analysis of tumor growth in Prdm1 fl/fl ( N = 26) and Prdm1 fl/fl CD19cre mice ( N = 30) implanted s.c. with 1 × 10 6 MC38 tumor cells per mouse. Data were pooled from 5 independent experiments. e , f Tumor sizes and weights on day 20 post-inoculation (DPI 20). In ( f ) N = 7 for Prdm1 fl/fl and 8 for Prdm1 fl/fl CD19cre groups. g , h Representative flow cytometry plots and frequencies of GC B cells (( g ); respective numbers of mice analyzed for Prdm1 fl/fl vs Prdm1 fl/fl CD19cre groups were as follows: D7: 7 vs 7, D18: 8 vs 8, D27: 9 vs 9) or plasma cells (( h ); respective numbers of mice analyzed for Prdm1 fl/fl vs Prdm1 fl/fl CD19cre groups were as follows: D7: 2 vs 2, D18: 8 vs 8, D27: 7 vs 7) in LNs on day 7, 18, 27 post inoculation of MC38 tumor cells. i , j Representative flow cytometry plots and frequency of tumor-infiltrating IFNγ + CD8 T cells ( i ) or IFNγ + CD4 T cells ( j ) from Prdm1 fl/fl ( N = 7) vs Prdm1 fl/fl CD19cre mice ( N = 6) on DPI 7. k , l Representative flow cytometry plots and frequency of tumor-infiltrating exhausted CD8 T cells (( k ); Prdm1 fl/fl ( N = 7) vs Prdm1 fl/fl CD19cre mice ( N = 7)) or IFNγ + CD4 T cells (( l ); Prdm1 fl/fl ( N = 12) vs Prdm1 fl/fl CD19cre mice ( N = 9)) on DPI 27. Flow cytometry data ( b , c and g – l ) were from at least 3 independent experiments. Each point in graphs ( b , c , f – l ) represents the value obtained in an independent mouse. Bars are presented as mean ± SEM. P values were calculated with the two-tailed unpaired t -test ( b , c , f , g and i – l ), Two-way ANOVA ( a , d , g and h ) and exact p value shown in figures. Source data are provided as a Source Data file.

Article Snippet: All samples were acquired on BD LSR2 flow cytometer (BD Biosciences), or Aurora spectral flow cytometry (Cytek Biosciences) and data were analyzed using Flowjo software (v10).

Techniques: Flow Cytometry, Clinical Proteomics, Two Tailed Test

Journal: Nature Communications

Article Title: Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity

doi: 10.1038/s41467-025-59622-4

Figure Lengend Snippet: a , b Analysis of tumor growth in MD4+ ( N = 18) and non-transgeneic MD4− ( N = 17) littermate mice implanted s.c. with 1 × 10 6 B16F10 tumor cells per mouse. Data were pooled from 2 independent experiments. b Tumor sizes (left) and weights (right) on DPI 19. c , d Accelerated growth of MC38 tumors in MD4 mice. MD4+ ( N = 17) and MD4− ( N = 17) mice were implanted s.c. with 1 × 10 6 MC38 tumor cells per mouse. Data were pooled from 2 independent experiments. d Tumor sizes (left) and weights (right) on DPI 19. e Histogram comparison of membrane-bound HEL (mHEL) expression in B16F10-mHEL and control B16F10 cells. f , g Analysis of tumor growth in MD4+ and MD4− mice implanted s.c. with 1 × 10 6 control B16F10 cells (B16F10-Ctrl) or with B16F10 cells stably expressing membrane-bound HEL (B16F10-mHEL). Data were pooled from 5 independent experiments. g Tumor sizes (left) and weights (right) on DPI 20. h Representative flow cytometry plots, number and frequency of GC B cells in draining LNs of MD4+ mice implanted with B16F10-mHEL or B16F10-Ctrl cells on DPI 18. i , j Frequency and number of activated CD86 + MHC-II + B cells ( i ) and CD80 + MHC-II + B cells ( j ) in draining LNs on DPI 18. k Representative flow cytometry plots and frequency of tumor-infiltrating CD80 + MHC-II + B cells, and CD80 expression on CD19 + MHC-II + B cells on DPI 18. l Representative flow cytometry plots and frequency of tumor-infiltrating CD86 + MHC-II + B cells, and CD86 expression on CD19 + MHC-II + B cells on DPI 18. m Proportion and number of plasma cells in draining LNs on DPI 18. n ELISA measurement of anti-HEL antibody in serum of MD4+ mice on DPI 18 of B16F10-mHEL or B16F10-Ctrl tumor cells. Each point in graphs ( b , d , g , h – n ) represents value obtained in an individual mouse. Flow cytometry and ELISA data were pooled from 3 independent experiments. Bars show mean ± SEM. P values were calculated with two-tailed unpaired t -test ( b , d , g , h – n ), two-tailed unpaired multiple t -tests with Holm–Sidak’s correction ( a , c , f ) and exact p value shown. Source data are provided as a Source Data file.

Article Snippet: All samples were acquired on BD LSR2 flow cytometer (BD Biosciences), or Aurora spectral flow cytometry (Cytek Biosciences) and data were analyzed using Flowjo software (v10).

Techniques: Comparison, Membrane, Expressing, Control, Stable Transfection, Flow Cytometry, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: Nature Communications

Article Title: Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity

doi: 10.1038/s41467-025-59622-4

Figure Lengend Snippet: a Effect of anti-MHC-II blockade on MC38 tumor growth was assessed by treating Prdm1 fl/fl and Prdm1 fl/fl CD19cre mice with anti-MHC-II antibody or IgG2b control on days 0, 3, 7, 10, 13, 16 post inoculation (the days of injection indicated with black arrows); data were pooled from 2 independent experiments. b Representative flow cytometry plots and frequency of CD80 + MHC-II + B cells in draining LNs of Prdm1 fl/fl ( N = 7) vs Prdm1 fl/fl CD19cre ( N = 7) mice on DPI 7. c CD80 expression on CD19 + MHC-II + B cells in draining LNs on DPI 7. d Frequency of tumor-infiltrating CD80 + MHC-II + B cells in Prdm1 fl/fl ( N = 7) vs Prdm1 fl/fl CD19cre ( N = 6) mice on DPI 27. e CD80 expression on tumor-infiltrating CD19 + MHC-II + B cells on DPI 27. f Frequency of tumor-infiltrating CD86 + MHC-II + B cells in Prdm1 fl/fl ( N = 7) vs Prdm1 fl/fl CD19cre ( N = 6) mice on DPI 27. g CD86 expression on tumor-infiltrating CD19 + MHC-II + B cells on DPI 27. Flow cytometry data are from at least 3 independent experiments. Each point in graphs ( b – g ) represents an individual mouse. Bars show mean ± SEM. P values were calculated with two-tailed unpaired t -test ( b – g ), two-tailed unpaired multiple t -tests with Holm–Sidak’s correction ( a ) with exact p values shown. Source data are provided as a Source Data file.

Article Snippet: All samples were acquired on BD LSR2 flow cytometer (BD Biosciences), or Aurora spectral flow cytometry (Cytek Biosciences) and data were analyzed using Flowjo software (v10).

Techniques: Control, Injection, Flow Cytometry, Expressing, Two Tailed Test

Journal: Nature Communications

Article Title: Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity

doi: 10.1038/s41467-025-59622-4

Figure Lengend Snippet: a On day 18 post-MC38 inoculation, representative flow cytometry plots and frequency of CD9 + CD148 + B cells in tumors. b Elevated frequency of CD9 + CD148 + TIL-Bs in Prdm1 fl/fl CD19cre compared to Prdm1 fl/fl mice, N = 10/group. c Analysis of expression of CD20, IgD, IgM, CD73, PD-L2, and CD80 on d18 CD9 + CD148 + TIL-Bs in Prdm1 fl/fl CD19cre mice. d Representative flow cytometry plots and quantification of CD9 + CD148 + B cells of Prdm1 fl/fl mice ( N = 8) and Prdm1 fl/fl CD19cre mice ( N = 9) in draining LNs on DPI 18. e CD73, PDL2 and CD80 expression on tumor-infiltrating or on draining LNs CD9 + CD148 + B cells at DPI 18 in Prdm1 fl/fl ( N = 8) vs Prdm1 fl/fl CD19cre mice (N = 9). f Frequency and number of CD9 + CD148 + B cells in draining LNs (left and middle) and the proportion of tumor-infiltrating CD9 + CD148 + B cells (right) in Prdm1 fl/fl ( N = 14) vs Prdm1 fl/fl CD19cre mice ( N = 12) on DPI 7. Flow cytometry data are from 3 independent experiments. Each point in graphs ( b , d – f ) represents an individual mouse. Bars show mean ± SEM. P values were calculated with two-tailed unpaired t -test ( b , d and f ), ordinary one-way ANOVA with Tukey’s multiple comparisons test ( e ) with exact p value shown, and n.s. denote P > 0.05. Source data are provided as a Source Data file.

Article Snippet: All samples were acquired on BD LSR2 flow cytometer (BD Biosciences), or Aurora spectral flow cytometry (Cytek Biosciences) and data were analyzed using Flowjo software (v10).

Techniques: Flow Cytometry, Expressing, Two Tailed Test

Journal: Nature Communications

Article Title: Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity

doi: 10.1038/s41467-025-59622-4

Figure Lengend Snippet: a C57BL/6 and Prdm1 fl/fl CD19cre mice were implanted with MC38 and given drinking water containing 0%, 0.4%, or 0.8% VPA from day 0. b Tumor weights. c Frequency and number of plasma cells in draining LNs of VPA-treated mice on day 27 post-MC38 inoculation. d Proportion and number of GCB in draining LNs on DPI 18, N = 13, no VPA; N = 11, 0.8% VPA. e Number of activated CD80 + MHC-II + B cells ( N = 10) and CD86 + MHC-II+ ( N = 13, no VPA; N = 11, 0.8% VPA) B cells in draining LNs on DPI 18. f On DPI 18, frequency of tumor-infiltrating CD80 + MHC-II + B cells, N = 13, no VPA; N = 11, 0.8% VPA, and CD80 expression on CD19 + MHC-II + TIL-B cells, N = 11/group. g Proportion of CD86 + MHC-II + B cells and CD86 level on CD19 + MHC-II + B cells within tumors. h Representative flow plots and frequency of CD9 + CD148 + TIL-B cells on DPI 18, N = 10. i Number and proportion of CD9 + CD148 + B cells in draining LNs on DPI 18, N = 5, no VPA; N = 7, 0.8% VPA. j Percentage of Treg cells within tumors on DPI 18. k Proportion of tumor-effector CD4 T cells, CD8 T cells and NK cells on DPI 18, N = 14, no VPA; N = 12, 0.8% VPA. l Representative flow cytometry plots and frequency of tumor-infiltrating CD11b + F4/80+ macrophages on DPI 18, N = 11, no VPA; N = 9, 0.8% VPA. m Ratio of CD86 + M1 macrophages and CD206 + M2 macrophages in tumor on DPI 18, N = 16, no VPA; N = 14, 0.8% VPA. n , o Analysis of tumor growth in C57BL/6, Jh −/− JCk −/ − mice, or Rag1 − /− mice implanted with MC38 ( n ) or B16F10 ( o ) tumor cells and given 0% or 0.8% VPA from day 0. p Spontaneous tumor growth in MMTV-PyMT mice treated with VPA. Water containing 0% or 0.8% VPA was provided starting at age of 6 weeks until experimental endpoints. Data were from 2 independent experiments ( n , o ). Flow cytometry data were from 2 to 3 independent experiments, and each dot in graphs ( b – m ) represents an individual mouse. Bars show mean ± SEM. P values were calculated with the two-tailed unpaired t -test (b– m ), two-tailed unpaired multiple t -tests with Holm–Sidak’s correction ( a , n – p ), p values shown, n.s. denotes P > 0.05.

Article Snippet: All samples were acquired on BD LSR2 flow cytometer (BD Biosciences), or Aurora spectral flow cytometry (Cytek Biosciences) and data were analyzed using Flowjo software (v10).

Techniques: Clinical Proteomics, Expressing, Flow Cytometry, Two Tailed Test

Journal: Biosensors

Article Title: Recent Developments (After 2020) in Flow Cytometry Worldwide and Within China

doi: 10.3390/bios15030156

Figure Lengend Snippet: A summary of the state-of-the-art instruments of flow cytometry, worldwide and within China.

Article Snippet: FP7000 [ ] , Sony , Spectral Flow Cytometry , 6 lasers and 182 detectors.

Techniques: Flow Cytometry, Fluorescence, Imaging, Virus